HIVManagement.org

 

Quick Menu / Table of Contents
Introduction Principles Management NRTI Info NNRTI Info
PI Info Fusion Inhibitors Coreceptor Inhibitors Integrase Inhibitors Drug Summary
Investigational Adherence Lab Evaluation Resistance Tests PEP
Antiretroviral Tables OI Prevention Vaccinations TB Therapy Hepatitis Therapy
OI Diagnosis OI Therapy Bibliography Links Palliative Therapy

 

fosamprenavir

Detailed Prescribing Information

 

 

Fosamprenavir = Lexiva

Dosing Forms 700 mg tablets, 50 mg/ml liquid
Dosing Without boosting: 2x700 mg twice a day with or without food

With boosting:

2 x 700 mg + ritonavir 1-2 x 100 mg, both once a day (for patients who are relatively antiretroviral naive only - specifically without protease inhibitor mutations)

or

1x700 mg + ritonavir 1x100 mg, both twice a day; use 3x100 mg ritonavir with concomitant efavirenz

Hepatic impairment: reduce dose to 1x700 twice a day in hepatic impairment (Pugh score 5-8)
Food dependence Fosamprenavir may be taken with or without food.
Adverse Effects Diarrhea, nausea & vomiting, rash

Also perioral paresthesia, hepatitis, fat redistribution, hyperlipidemia, Type 2 diabetes

Contraindications Rifampin (decreases fosamprenavir levels by up to 80%)

Fosamprenavir should not be used in severe hepatic impairment (Pugh score 9-12)

Interactions Fosamprenavir levels are decreased by efavirenz (use boosted dosing above)

Fosamprenavir levels are increased by delavirdine

Fosamprenavir decreases lopinavir levels by 60% and fosamprenavir levels are decreased by up to 70% by lopinavir

No data: nevirapine, atazanavir (June 2004)
Suggested laboratory evaluations Liver profile and glucose monthly x 3 months, then every 3-4 months; lipid profile q3-4 months
Warnings Concomitant lopinavir/ritonavir (Kaletra) is not recommended due to decreased and possibly subtherapeutic lopinavir levels that result.
There appears to be a chance of cross-hypersensitivity with sulfonamides (16% vs 14% incidence of reaction in persons with a history of sulfonamide hypersensitivity fosamprenavir vs placebo, respectively)
Usage Suggestions This drug may largely supplant amprenavir due to decreased pill burden and better tolerance.
Fosamprenavir was approved for pediatric use in 2007.1
Full Prescribing Information http://www.lexiva.com


 

Links to Antiretroviral Sections (click on anything)
Nucleoside & Nucleotide Reverse Transcriptase Inhibitors (NRTI) & NNRTI/NRTI Combinations
AZT  |  ddC  |  ddI  |  d4T  |  3TC  |  ABC  |  FTC  |  TDF  |  Combivir  |  Trizivir  |  Epzicom  |  Truvada  |  Atripla
Nonnucleoside Reverse Transcriptase Inhibitors (NNRTI)
efavirenz  |  nevirapine  |  delavirdine
Protease Inhibitors (PI)  Boosted Protease Inhibitors
saquinavir  indinavir  |  ritonavir  |  nelfinavir  |  amprenavir  |  lopinavir + ritonavir  |  atazanavir  |  fosamprenavir  | tipranavir
Fusion Inhibitors
enfuvirtide

 

 

Quick Menu / Table of Contents
Introduction Principles Management NRTI Info NNRTI Info
PI Info Fusion Inhibitors Coreceptor Inhibitors Integrase Inhibitors Drug Summary
Investigational Adherence Lab Evaluation Resistance Tests PEP
Antiretroviral Tables OI Prevention Vaccinations TB Therapy Hepatitis Therapy
OI Diagnosis OI Therapy Bibliography Links Palliative Therapy

 

Updated 1.11.2008